Chronically elevated free fatty acids (FFAs) are believed to have a detrimental effect on glucose-stimulated insulin secretion (GSIS), β-cell function, and β-cell survival in type 2 diabetes, a phenomenon often referred to as lipotoxicity.
Introduction
Elevated plasma free fatty acids (FFAs), caused by the excessive release of fatty acids from an expanded adipose tissue mass, are often linked to β-cell dysfunction in diabetes [1, 2] . β-cell mass appears to be reduced in many cases of type 2 diabetic patients [3] [4] [5] and considering that type 2 diabetic patients usually are obese, it is unclear whether this defect arises due to genetic and/or environmental factors. The respective role of genetic and environmental factors is controversial, since most of the previous studies have been performed in animal models with a genetic predisposition to diabetes/obesity. Considering the fact that non-diabetic obese subjects show an increased β-cell volume [6] , a genetic predisposition may be essential to β-cell failure and thereby β-cell mass reduction. β-cell failure in type 2 diabetes has been previously suggested to be induced by increased FFAs alone [7, 8] , or in synergy with glucotoxicity [9] [10] [11] [12] . Whether FFAs alter β-cell function and apoptosis in synergy with glucose, or by its own right, thus remains controversial.
Pioglitazone, a PPAR-γ agonist (member of the TZD family), seems to attenuate FFA-induced apoptosis in β-cells [13] . In contrast, troglitazone (another member of the TZD family) showed no protective effect against FFA-induced toxicity in β-cells [14] .
Exenatide (synthetic exendin-4), an incretin mimetic and GLP-1 receptor agonist, has been shown to increase β-cell mass by enhancing proliferation/neogenesis, and its function [15] [16] [17] [18] [19] . Moreover, it stimulates β-cell fat metabolism [20, 21] and protects against β-cell apoptosis [22, 23] . The mechanism and the protective effect of these drugs against lipotoxicity in the β-cell remain unclear.
The aim of this study was to determine the long-term in vitro effect of palmitate, with or without pioglitazone or exenatide, on global gene expression in human pancreatic islets from healthy non-obese non-diabetic and non-obese diabetic subjects by using microarray technology. We thus wanted to to identify genes influenced by palmitate, pioglitazone and/or exenatide, and also to compare the expression of genes in between the diabetic and non-diabetic groups of conditions.
Materials and Methods

Materials
The chemicals were obtained from the following sources: Collagenase type CLS (EC 3.4.24.3) from Roche (Mannheim, Germany). Culture medium RPMI-1640, fetal calf serum, L-glutamine, benzylpenicillin and streptomycin from Flow Laboratories (Irvine, *Corresponding author: Åke Sjöholm, Karolinska Institutet, Department of Internal Medicine, Stockholm South Hospital, SE-118 83 Stockholm, Sweden, Tel: +4686163219; Fax: +4686163146; E-mail: ake.sjoholm@ki.se
Data analysis
Data normalization and statistical analysis were performed using GeneSpring 7.3 software (Agilent, Santa Clara, CA). The data were normalized by utilizing the 50 th percentile (per chip normalization) and the normalization to median (per gene normalization). To determine genes differentially expressed across conditions, the ANOVA test (considering False Discovery Rate, FDR) at P values <0.05, and a fold change of >1.5 were performed. Moreover, these genes were assigned to functional groups as described in GeneSpring (Agilent, Santa Clara, CA), NetAffx (Affymetrix) and other databases. Detailed descriptions of a selection of the differentially expressed transcripts, classified according to function and average fold change, are listed in Tables 1-4 and supplementary cDNA synthesis RNA was denatured for 10 min at 65°C and immediately chilled on ice. First strand cDNA synthesis was performed in a 20 µl reaction mixture containing 2 µg total RNA in a solution of 10 µl, 4 µl 5 × reverse transcriptase buffer (Invitrogen, Carlsbad, CA), 10 mM deoxynucleoside triphosphate, 1 µl random hexamer primers (100 pmol/µl), 1.5 µl dithiothreitol (Amersham Pharmacia Biotech, Piscataway, NJ) (100 mmol/l) and 1 µl RT1 reverse transcriptase (200 U/ µl; Invitrogen, Carlsbad, CA). The reagents were mixed and incubated at 37°C for 45 min. cDNA solutions were incubated for 5 min at 95°C to inactivate reverse transcriptase and then stored at -20°C.
Quantitative real-time PCR
Expression of selected genes ( Table 5 ) was performed from total RNA using an ABI Prism 7700 polymerase chain reaction machine (PE Applied Biosystems, Foster City, CA). These genes were selected based on differential expression grounded on statistical analysis and fold change threshold, a select range of intensities, biological interest and potential roles in diabetes, and primer availability. Results are expressed relative to with and the ratio of different groups ( Table 5) .
cDNA samples were used as templates whereas an internal control (18S rRNA), was quantified as a positive control and used for normalization of the different template values. 18S rRNA was chosen among 34 candidate control genes previously checked using the TaqMan Human Endogenous Control Plate. Data were normalized using 18S rRNA because of the consistency of its level from sample to sample. To amplify the cDNA, 100 ng of the reversed transcribed cDNA from each sample were subjected to 40 cycles of real-time quantitative PCR in 20 µl of total reaction volume. Moreover, GADD45B, GAPDH, PPY, REG3A, TXNIP, CEL, ARNT, ISL1, TCF7L2/TCF4, and DAD1 probes and primers were used to flank the target DNA sequence. Each realtime TaqMan PCR reaction (20 µl) consisted of the cDNA template (except for the negative controls) and H 2 O to final volume of 9 µl, 1µl of TaqMan ® Gene Expression Assay in 20 X format (containing the target primers and TaqMan probe) and 10 µl of TaqMan Fast Universal PCR Master Mix (2X), No AmpErase UNG (According to manufacturer's instruction "TaqMan Gene Expression Assays", Applied Biosystems). Aliquots were then amplified by an initial period of 2 min at 50°C and 10 min at 95°C followed by 40 concurrent cycles involving denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 min The samples were placed in 96-well optical PCR plate (N 801-0560, Perkin Elmer) and amplified in an automated fluorometer (ABI PRISM 7700 Sequence Detection System, Applied Biosystems). For relative quantification of different mRNAs, the following arithmetic formula was used according to the Perkin-Elmer Instruction Manual of 1997: Relative alteration = 2 -∆∆CT , where Ct is the point (cycle) at which the amplification plot crosses the threshold, which is defined as ∆Ct = (Ct_sample2 -Ct_18S rRNA) -(Ct_sample1 Ct_18S rRNA). Therefore, the final value indicates an increase or decrease in mRNA for selected genes after normalization against 18S rRNA ( Table 5 ).
Statistical analysis
Means ± S.E.M. were calculated and groups of data compared using Student's t-test for paired or unpaired data. Differences were deemed statistically significant when P<0.05.
Results
Microarray analysis of global gene expression changes regulated by palmitate, pioglitazone and exenatide in normal and diabetic human islets
To gain detailed insight into the molecular mechanisms of palmitate, pioglitazone and exenatide action in isolated islets, we performed global gene expression profiling studies using Affymetrix GeneChip technology. Among the ~ 47,000 transcripts interrogated on the array, there were over 2,700 genes with known or inferred function that were affected by both pioglitazone and exenatide treatment, during palmitate exposure ( Figure 1) . A large number of differentially expressed genes belonged to several functional categories, such as epigenetic regulation of gene expression, cell proliferation and differentiation, metabolism, response to stimulus, transport, and signal transduction (supplementary Figure 2 ). Interestingly, epigenetic regulation of gene expression turned out to be the largest and most influenced transcript group in this study. The expressional profiles for these genes or ESTs are listed in Table 1 to 4 and supplementary Tables  6-13 . In none of the analyses, the apoptotic pathway was noticeably influenced either by palmitate, pioglitazone or exenatide.
Differential expression of a subset of genes confirmed with qrt-PCR
To confirm the gene regulation observed with microarray analysis, we performed qRT-PCR on samples for selected genes that were differently regulated on the microarrays. The results generated by qRT-PCR showed a highly significant correlation between the levels of gene expression measured by both methods (Table 5 ).
Discussion
The interaction between the genetic predisposition to β-cell failure with environmental or lifestyle factors appears to lead to diabetes Mitogen-activated protein kinase associated protein 1 (MAPKAP1) NM_024117 1.8 pathogenesis. In the present study, we identify a subset of genes that seems to be involved in maladaptive metabolic alterations underlying the lipotoxic state leading to β-cell dysfunction and diabetes.
Pancreatic polypeptide (PPY) belongs to the NPY family and is expressed in the pancreatic islets of Langerhans. Moreover, PPY is released from the pancreas in response to a meal, specially by fat [24, 25] . PPY decreases food intake and increases energy expenditure [26, 27] . In this study, PPY expression was up-regulated in non-diabetic islets by pioglitazone and exenatide in the presence of palmitate (Table   4 ), but not by palmitate alone (epigenetic gene regulation pathway). This induction of PPY gene expression could influence pancreatic and gastric hormone release, and modulate different physiological processes. Interestingly, palmitate had no effect alone on PPY gene expression, possibly due to the absence of obesity, considering that obese subjects have lower serum levels of PPY [28, 29] . Also, the PPY gene could be silenced by palmitate in non-diabetic islets. On the other hand, PPY was up-regulated by palmitate ( linkage of the region containing PPY [30] and also genetic association of this gene with type 2 diabetes [31] [32] [33] , suggest that PPY may be pathogenetically and therapeutically relevant in diabetes.
Transcription factor 7-like 2 (TCF7L2/TCF4), identified as the most important type 2 diabetes susceptibility gene to date [34] , is involved in Wnt signaling induced β-cell proliferation [35, 36] of TCF7L2/TCF4 transcript was induced by palmitate in diabetic islets in this study ( Table 2) , whereas in non-diabetic islets it remained unchanged. In addition, exenatide reduced the gene expression of TCF7L2/TCF4 in both diabetic (Table 1 ) and non-diabetic (Table  3) islets incubated with palmitate. Moreover, pioglitazone downregulated TCF7L2/TCF4 expression in the presence of palmitate in diabetic islets ( Table 1 ). The up-regulated level of TCF7L2/TCF4 gene expression by palmitate noticed in our diabetic islets is in agreement with previous result where TCF7L2/TCF4 was overexpressed in type 2 diabetic human islets in response to a variety of stimulus [37] . Moreover, according to Lyssenko et al. overexpression of TCF7L2/ TCF4 in the β-cell reduces insulin secretion, suggesting that its upregulation by palmitate might be involved in β-cell dysfunction evoked by the fatty acid and perhaps also relevant in diabetic lipotoxicity in patients in whom β-cell dysfunction occur. The down-regulation of the palmitate-induced TCF7L2/TCF4 elevation by exenatide and pioglitazone observed in our human islets is also very interesting as it might contribute to the beneficial long-term influence by these drugs on β-cell function and viability.
Regenerating islet-derived 3 alpha (REG3A) is a pancreatic secretory protein that seems to be involved in β-cell proliferation and differentiation [38] via a cell surface Reg receptor [39] . In the current study, REG3A expression was up-regulated by palmitate in diabetic islets ( Table 2 ). Taking into account this and also another study, where similar effect has been seen for the other members of the REG family in the presence of hyperglycemia [40] , it may indicate the β-cells attempt to ameliorate lipoapoptosis through stimulation of β-cell proliferation. Furthermore, elevated expression of REG3A that results in islet neogeneis, growth, and/or protection has also been reported by others [38, 41] . Both pioglitazone and exenatide induced REG3A expression in non-diabetic islets exposed to palmitate (Table 4) , and reduced REG3A expression in diabetic islets exposed to palmitate (Table 1) . Possibly, pioglitazone and exenatide contribute to maintenance of β-cell mass through induction of REG3A when islets become exposed to lipotoxicity and so signaling through the REG3A pathway might be one mechanism by which these drugs exert their beneficial influences on the β-cell.
Growth arrest and DNA-damage-inducible beta (GADD45B) is a member of the GADD45 nuclear protein family that is involved in β-cell growth arrest, DNA repair, and apoptosis [42] . In this study, the expression of GADD45B was slightly up-regulated by palmitate in diabetic islets (Table 2) . A similar effect in response to the cytotoxic IL-1β in INS-1E cells has recently been reported [43] . Both pioglitazone and exenatide reduced GADD45B expression in diabetic islets exposed to palmitate ( Table 1 ). This may indicate that pioglitazone and exenatide, by normalizing the overexpression of GADD45B by palmitate, attempt to restore the balance between apoptosis and proliferation/survival in these islets. Considering that GADD45 family proteins are coactivators for RXR or PPAR activation [44] , the modulation of GADD45B expression could influence nuclear hormone receptor activity and their involvment in fatty acid metabolism, apoptosis/cell survival, and insulin production/secretion. Thioredoxin interacting protein (TXNIP) regulates the cellular redox state and mediates oxidative stress [45] [46] [47] [48] [49] . Our results show that TXNIP was up-regulated by palmitate in both diabetic ( Table 2) and non-diabetic (Table 4) islets. Previous reports have shown TXNIP upregulation by glucose [50, 51] , and it appears now that FFAs impose similar effects in the β-cell. Considering that TXNIP overexpression induces apoptosis in β-cells in response to glucose [50] , and impairs glucose-induced insulin secretion [52] , this could also be the ultimate scenario for β-cells exposed to FFAs. These results underline the importance of TXNIP for β-cell survival and insulin secretion. Our results reveal that TXNIP expression was reduced by both pioglitazone and exenatide in diabetic islets exposed to palmitate (Table 1) , whereas it was induced by these drugs in the presence of palmitate in nondiabetic islets (Table 4 ). It seems that both pioglitazone and exenatide were able to reduce and normalize the overexpression of TXNIP induced by palmitate in diabetic islets and it is conceivable that this mechanism might in part explain the positive impact of these drugs in terms of β-cell funtion and insulin secretion possibly due to existence of diabetes (a certain genetic background) and also hyperglycemia in diabetic subjects. This effect of exenatide has been reported previously in pancreatic islets [53] .
Aryl hydrocarbon receptor nuclear translocator (ARNT), a.k.a. hypoxia-inducible factor (HIF), form heterodimeric complexes that directly regulate the expression of genes involved in glucose transport and glucose metabolism [54] . Moreover, the ARNT gene is located in a chromosomal region that shows strong linkage to type 2 diabetes [55] . Our present results show that ARNT gene expression was reduced by palmitate in diabetic islets (Table 1) . ARNT expression has previously been reported to be significantly decreased in islets from type 2 patients, ARNT gene silencing in isolated β-cells was found to grossly impair glucose-stimulated insulin secretion, and ARNT knock-out animals showed severe glucose intolerance [56] . Our findings suggest that palmitate, which is in excess in diabetic patients' serum due to their diabetic dyslipidemia, might be one factor that contributes to this ARNT down-regulation in diabetic islets. More importantly, ARNT down-regulation by palmitate was normalized by both pioglitazone and exenatide in our diabetic islets ( Table 2) . This may indicate one important molecular target for pioglitazone and exenatide in islets, by which these drugs maintain optimal insulin secretion and β-cell function.
Epidermal growth factor receptor (EGFR) is involved in cellular differentiation, proliferation, and survival in many cell types of epithelial origin through interactions with EGF [57] [58] [59] . Also, EGFR transactivation in GLP-1-induced β-cell proliferation has been reported [60] . The gene expression of EGFR in our study was slightly up-regulated by palmitate in diabetic islets (Table 2) , whereas in non-diabetic islets it remained unchanged. This may reflect the β-cell's attempt to diminish the apoptotic effect of palmitate in diabetic situations by stimulating the proliferation and β-cell survival trough induction of EGFR gene expression. On the other hand, the unchanged level of EGFR expression in non-diabetic islets could be due to the silencing effect of palmitate on the gene expression of EGFR. The expression of EGFR was reduced by pioglitazone in diabetic islets (Table 1) , whereas it was induced by both pioglitazone and exenatide in non-diabetic islets (Table 4) exposed to palmitate. The latter may reflect the protective effects conferred by pioglitazone and exenatide in β-cells through maintaining the balance between their apoptosis and proliferation.
Carboxyl ester lipase (CEL), a lipolytical enzyme, highly expressed and secreted from pancreas, contributes to the digestion of dietary fat [61, 62] . As exocrine pancreatic dysfunction is common in diabetes, considerable interest for CEL in islet biology arose when it was discovered that CEL mutations occur in a hereditary syndrome of diabetes and exocrine pancreatic dysfunction [63] . CEL mutations are overrepresented in MODY patients with β-cell failure (63) . In the current study, CEL expression was not altered by palmitate in diabetic or non-diabetic islets, possibly due to silencing effect of palmitate. However, the CEL gene expression was up-regulated by pioglitazone and exenatide in both diabetic ( Table 2 ) and non-diabetic (Table 4 ) islets exposed to palmitate. As studies of the role of CEL in islet biology are still in their infancy, it seems warranted to pursue this track in future efforts to determine whether the CEL upregulation observed in islets exposed to pioglitazone and exenatide is causally linked to protection by these drugs against β-cell dysfunction in lipotoxicity.
Acetyl-Coenzyme A carboxylase alpha (ACACA) regulates fatty acid biosynthesis [64, 65] . In the current study, ACACA gene expression was down-regulated by palmitate in diabetic islets (Table  1) , thus confirming results in the INS-l β-cell line [66] . This indicates stimulation of fatty acid oxidation to produce energy at the expense of lipid synthesis and contributing to impaired glucose-sensitive insulin secretion [66] . Previous studies have shown similar results when polyunsaturated fatty acids reduced the transcriptional rates of lipogenic enzymes [67] . On the other hand, studies on the INS-l β-cell line [68] , and also rats fed with high-carbohydrate diet [67] , have indicated glucose as a potent inducer of ACACA gene expression. Interestingly, both pioglitazone and exenatide up-regulated ACACA gene expression suppressed by palmitate in diabetic islets ( Table 2 ). This indicates the normalizing effect by these drugs on palmitateinduced imbalance between fatty acid breakdown and synthesis by increasing lipogenesis, thereby probably positively impacting long term β-cell function and survival by ameliorating lipotoxicity and restoring glucose-sensitivity. Commensurate with such a role, previous findings using ACAC gene silencing have revealed an essential role for ACAC in nutrient-induced insulin secretion [69, 70] .
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a classical glycolytic enzyme involved in β-cell fuel sensing and energy production that yields high-energy phosphate molecules [71] . Moreover, GAPDH is also involved in several other pathways, including apoptosis by its translocation into the nucleus, protein phosphotransferase/kinase reactions, translational control of gene expression, DNA replication and repair [72] [73] [74] . In this study, GAPDH gene expression was upregulated by palmitate in diabetic islets (Table 4) , whereas it remained unchanged in non-diabetic islets. This may reflect an attempt of the diabetic β-cell to sustain ATP production to endure lipotoxicity, whereas in non-diabetic islets GAPDH transcription seems to be silenced. Furthermore, the influence of lipotoxicity on transcriptional regulation of GAPDH gene expression appear to be different from the translational regulation, considering that palmitoyl-CoA has been reported to inhibit GAPDH enzyme activity [75] . Both pioglitazone and exenatide enhanced GAPDH gene expression in non-diabetic islets exposed to palmitate (Table 4 ). Possibly the GAPDH gene that was silenced by palmitate in these normal islets became activated by the drugs to cope with lipotoxicity, thus promoting β-cell survival by stimulating energy production. On the other hand, exenatide upregulated ( Table 2 ) while pioglitazone down-regulated (Table 1) GAPDH gene expression in diabetic islets exposed to palmitate. It is difficult to speculate why these drugs act differently in this scenario, but one conceivable explanation could be that they might act through different pathways (as mentioned above) to cope with lipotoxicity and to protect the β-cell.
We noticed small differences between the diabetic and non-diabetic samples when looking at the genes involved in the inflammatory process, as previously suggested [76] . This could perhaps suggest the presence of a mild inflammation in islets from T2D patients compared to normal samples. In agreement with a previous study [77] , in our study Chemokine (C-X-C motif) ligand 2 (CXCL2) gene expression was induced (10.7 fold) by palmitate in diabetic islets ( Table 2) . Whether the induction of the inflammatory genes in islets from T2D patients could be the result of in vivo exposure to saturated NEFA and whether this inflammation causes loss of functional β-cell mass and thereby T2D remains to be elucidated and needs to be further investigated.
In this study, the expression of a number of key genes altered by palmitate, pioglitazone and/or exenatide were classified into epigenetic regulation of gene expression, which also belong to major pathways involved in lipid metabolism. We identified epigenetic targets with known significance in β-cell biology that are up-regulated, downregulated or silenced by palmitate, pioglitazone and/or exenatide. The function and survival of the human β-cell seem to be regulated directly through epigenetic control of expression of genes involved in growth, proliferation, and differentiation rather than a direct effect on the apoptotic pathway. Since regulation of gene expression seems to be tightly under the epigenetic control and individually programmed, it might be different in different individuals and not totally be comparable to each other/generalized, which needs to be addressed in future investigations. FFAs seem to contribute and play an important role in the development of β-cell failure in synergy with hyperglycemia, in obese individuals, or in subjects who are genetically more predisposed to type 2 diabetes. Modern antidiabetic drugs such as pioglitazone and exenatide appear to normalize these epigenetic misregulations induced by lipotoxicity in the human β-cell. These identified β-cell genes may be harnessed to advantage in the development of novel diagnostic biomarkers or targeted therapeutics for type 2 diabetes based upon promotion of human β-cell function, survival, and proliferation.
